Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (Nasdaq: NRIX) announced that its CEO, Dr. Arthur T. Sands, will present a corporate update at the Jefferies Global Healthcare Conference. This presentation is scheduled for June 5, 2024, at 5:30 p.m. ET in New York City. The event will be webcast live, and an archived version will be available for 30 days post-event. Nurix is a clinical-stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases. The announcement highlights the company's continued efforts to engage with the medical and financial communities.
Nurix Therapeutics announced the appointments of Paula G. O’Connor, M.D., as Chief Medical Officer, and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer.
Dr. O’Connor, with over 15 years of drug development experience, joined Nurix in 2022 and has held senior positions at Protagonist Therapeutics and Genentech. Dr. Phiasivongsa, also joining in 2022, has extensive expertise in CMC development and has held leadership roles at Kronos Bio and Principia Biopharma.
These appointments aim to accelerate the development of Nurix's NX-5948 program targeting B cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
Nurix Therapeutics announced a transition in its board leadership. David L. Lacey stepped down as chair, continuing his role as a board member and committee leader. Julia P. Gregory, a current board member since 2019, was unanimously elected as the new board chair. Nurix's CEO, Arthur T. Sands, praised Lacey's guidance and expressed confidence in Gregory's ability to drive the company forward. Gregory brings extensive experience, having held leadership roles at ContraFect , Five Prime Therapeutics, and Lexicon Pharmaceuticals. The company is focused on developing targeted protein modulation drugs for cancer and inflammatory diseases.
Nurix Therapeutics will present new data on their selective BTK degrader, NX-5948, at the European Hematology Association Congress (EHA2024) from June 13-16, 2024, in Madrid, Spain, and virtually.
The data, from an ongoing Phase 1a/b study, show a 70% overall response rate in 10 heavily pretreated CLL patients with resistance mutations to BTK inhibitors. The responses are deepening with longer treatment duration, and all responses are ongoing as of January 2024.
The presentation will also include additional data at higher dose levels and longer treatment durations. Nurix will host a webcast conference call on June 16 following the presentation.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) will participate in the RBC Capital Markets Global Healthcare Conference. Arthur T. Sands, M.D., Ph.D., Nurix's CEO, will be in a fireside chat on May 14, 2024. The event will be webcast live and accessible via the Investors section of the Nurix website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.